Brent Rice - Autolus Therapeutics Chief VP
| AUTL Stock | USD 1.41 0.01 0.71% |
Insider
Brent Rice is Chief VP of Autolus Therapeutics
| Age | 59 |
| Address | The Mediaworks, London, United Kingdom, W12 7FP |
| Phone | 44 20 3829 6230 |
| Web | https://www.autolus.com |
Autolus Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2299) % which means that it has lost $0.2299 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6056) %, meaning that it created substantial loss on money invested by shareholders. Autolus Therapeutics' management efficiency ratios could be used to measure how well Autolus Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.27. The value of Return On Capital Employed is expected to slide to -0.4. At this time, Autolus Therapeutics' Debt To Assets are quite stable compared to the past year. Fixed Asset Turnover is expected to rise to 0.13 this year, although the value of Other Current Assets will most likely fall to about 13 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Arnon Rosenthal | Annexon | 68 | |
| Gwen Carscadden | RAPT Therapeutics | 65 | |
| Jessie MBA | Rocket Pharmaceuticals | N/A | |
| MS MBA | ADC Therapeutics SA | 53 | |
| CPE MBA | Aura Biosciences | 57 | |
| Ted Yednock | Annexon | 68 | |
| Dirk Brockstedt | RAPT Therapeutics | 57 | |
| Robert Schmidt | ADC Therapeutics SA | 43 | |
| Amanda Hamilton | ADC Therapeutics SA | N/A | |
| Paulo Carvalho | Aura Biosciences | N/A | |
| MBA MBA | Solid Biosciences LLC | 65 | |
| Richard Onyett | ADC Therapeutics SA | 73 | |
| Claudia Drayton | QuantumSi | 56 | |
| MBA MBA | Rocket Pharmaceuticals | 43 | |
| Michael Mulkerrin | ADC Therapeutics SA | 69 | |
| Mark Rosch | Aura Biosciences | 60 | |
| Larry Mattheakis | Annexon | 67 | |
| Michele MBA | Aura Biosciences | N/A | |
| Kimberly Pope | ADC Therapeutics SA | 59 | |
| CPA CPA | Rocket Pharmaceuticals | 51 | |
| Annie Ganot | Solid Biosciences LLC | N/A | |
Management Performance
| Return On Equity | -0.61 | ||||
| Return On Asset | -0.23 |
Autolus Therapeutics Leadership Team
Elected by the shareholders, the Autolus Therapeutics' board of directors comprises two types of representatives: Autolus Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Autolus. The board's role is to monitor Autolus Therapeutics' management team and ensure that shareholders' interests are well served. Autolus Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Autolus Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Olivia Manser, Director Relations | ||
| David Brochu, Senior Officer | ||
| Chris Williams, Senior Development | ||
| Veronica Hersberger, Senior Affairs | ||
| Robert Dolski, Chief Officer | ||
| Lucinda Crabtree, Chief Officer | ||
| Christopher Williams, Chief Officer | ||
| Miranda Neville, Chief Officer | ||
| Robert MD, Executive Director | ||
| Alexander Swan, Senior Officer | ||
| Christian Itin, CEO Director | ||
| MBBS MD, Senior Founder | ||
| Brent Rice, Chief VP | ||
| Vesna Cizej, Senior Development | ||
| Christopher Vann, Senior COO | ||
| Alex Driggs, Senior Secretary | ||
| Matthias MD, Senior Officer | ||
| Patrick McIlvenny, Senior Officer | ||
| Dilip Patel, Senior Srategy | ||
| ACA BEcon, Advisor |
Autolus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Autolus Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.61 | ||||
| Return On Asset | -0.23 | ||||
| Operating Margin | (3.38) % | ||||
| Current Valuation | 73.68 M | ||||
| Shares Outstanding | 266.14 M | ||||
| Shares Owned By Insiders | 5.56 % | ||||
| Shares Owned By Institutions | 70.89 % | ||||
| Number Of Shares Shorted | 15.44 M | ||||
| Price To Earning | (19.33) X | ||||
| Price To Book | 1.41 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Autolus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Autolus Therapeutics. If investors know Autolus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Autolus Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (0.83) | Revenue Per Share | Quarterly Revenue Growth (0.11) | Return On Assets | Return On Equity |
The market value of Autolus Therapeutics is measured differently than its book value, which is the value of Autolus that is recorded on the company's balance sheet. Investors also form their own opinion of Autolus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Autolus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Autolus Therapeutics' market value can be influenced by many factors that don't directly affect Autolus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Autolus Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Autolus Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Autolus Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.